ABCL
- AbCellera Biologics Inc.
()
Overview
Company Summary
AbCellera Biologics Inc. (ABCL) is a biotechnology company that specializes in the field of antibody discovery. The company uses advanced technologies and innovative approaches to identify and analyze antibodies present in the natural immune systems of a variety of organisms, particularly humans.
The main focus of AbCellera is to discover and develop therapeutic antibodies that can be used to treat various diseases, including cancer, infectious diseases, autoimmune disorders, and more. They aim to provide novel solutions by leveraging their expertise in antibody discovery and human immune system analysis.
AbCellera's unique platform combines high-throughput microfluidics, genomics, proteomics, and data analysis techniques. By screening millions of single cells and analyzing their genetic information, the company can identify rare and highly effective antibodies that have the potential to be developed into therapeutic drugs.
Once promising antibodies are discovered, AbCellera partners with pharmaceutical and biotech companies to further develop and optimize these candidates. Collaboration with these partners allows for scaled-up manufacturing, preclinical and clinical testing, regulatory approvals, and commercialization of the therapeutic antibodies.
In addition to therapeutic antibody discovery, AbCellera also provides other services, including immune profiling, antigen discovery, and screening of potential antibody-based products. They have built a reputation for their ability to rapidly screen large antibody libraries, which has proven highly valuable during outbreaks such as the COVID-19 pandemic.
Overall, AbCellera Biologics is a leading company in the field of antibody discovery and development. Their goal is to revolutionize medicine by harnessing the power of the immune system to combat diseases and improve human health.